Meeting
2023 ASCO Annual Meeting
[18F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma.
Authors
Sabine Breukers
The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands
Sabine Breukers , Robert D. Crommelin , Laura Smit , J.P. De Boer , Arash Navran , Winan J. van Houdt , Remco de Bree , Lot A. Devriese , John B. A. G. Haanen , Charlotte L. Zuur , Maurits Wondergem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04620200
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9584)
DOI
10.1200/JCO.2023.41.16_suppl.9584
Abstract #
9584
Poster Bd #
347
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
First Author: Milton Jose De Barros E Silva
Poster
2023 ASCO Annual Meeting
Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma.
First Author: Antonio D'Alessio
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.
First Author: Kruti Bhagirath Vora
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
First Author: Yara L. Verschoor